Clinical Trial

Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

Study acronym: VIVID-6
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-08-04; most recent amendment 2026-04-02.
Status change: Not Yet Recruiting → Recruiting 2025-08-14
Trial Details
NCT Number NCT07115004
Lead Sponsor Vega Therapeutics, Inc
Conditions Von Willebrand Disease (VWD)
Enrollment 60 participants
Start Date 2025-10-15
Primary Completion 2028-10 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-03